OncoSil Medical (ASX: OSL) managing director Dr. Neil Frazer has bought 150,148 shares in the company in on market trade.
He paid a total of $20,479.98 for the shares, or an average consideration of $0.136 each. He now holds 6,150,148 shares in the company.
The company had recently closed an oversubscribed placement to raise funds for the global Registration Study for its OncoSil™ localised radiation therapy for the treatment of pancreatic cancer.
Dr. Frazer has 25 years of drug development experience in Europe and the United States. He has conducted numerous Phase I - IV Studies that have led to product registration in numerous jurisdictions.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX "Small and Mid-cap" stocks with distribution in Australia, UK, North America and Hong Kong / China.